Burkholderia pseudomallei and Burkholderia mallei: Melioidosis and Glanders

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 2541-2551.e2

  Currie, Bart J ^a  

^a ROYAL DARWIN HOSPITAL   (Australia)

Author keywords

Burkholderia mallei; Burkholderia pseudomallei; Glanders; Melioidosis; Tropical infections

Indexed keywords

EID: 84944520510     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00223-X     Document Type: Chapter

References (184)

1. Wiersinga WJ, Currie BJ, Peacock SJ Melioidosis. N Engl J Med 2012, 367:1030-1039.
2. Whitmore A, Krishnaswami CS An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. Indian Med Gaz 1912, 47:262-267.
3. Stanton AT, Fletcher W Melioidosis, a new disease of the tropics. Trans Fourth Congr Far East Assoc Trop Med 1921, 2:196-198.
4. Leelarasamee A, Bovornkitti S Melioidosis: review and update. Rev Infect Dis 1989, 11:413-425.
5. Currie BJ, Ward L, Cheng AC The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20-year Darwin prospective study. PLoS Negl Trop Dis 2010, 4:e900.
6. Punyagupta S Melioidosis: review of 686 cases and presentation of a new clinical classification. Melioidosis 1989, 217-229. Bangkok Medical, Bangkok. S. Punyagupta, T. Sirisanthana, B. Stapatayavong (Eds.).
7. Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989, 159:890-899.
8. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, et al. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg 2010, 82:1113-1117.
9. Leelarasamee A Melioidosis in Southeast Asia. Acta Trop 2000, 74:129-132.
10. Puthucheary SD, Parasakthi N, Lee MK Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans R Soc Trop Med Hyg 1992, 86:683-685.
11. Yap EH, Chan YC, Goh KT, et al. Sudden unexplained death syndrome-a new manifestation in melioidosis?. Epidemiol Infect 1991, 107:577-584.
12. Lo TJ, Ang LW, James L, Goh KT Melioidosis in a tropical city state, Singapore. Emerg Infect Dis 2009, 15:1645-1647.
13. Dance DA Melioidosis as an emerging global problem. Acta Trop 2000, 74:115-119.
14. Lee N, Wu JL, Lee CH, et al. Pseudomonas pseudomallei infection from drowning: the first reported case in Taiwan. J Clin Microbiol 1985, 22:352-354.
15. Chen YL, Lin YC, Chen YS, et al. Characterisation of predominant molecular patterns of Burkholderia pseu-domallei in Taiwan. Trans R Soc Trop Med Hyg 2013, 107:165-169.
16. Parry CM, Wuthiekanun V, Hoa NT, et al. Melioidosis in Southern Vietnam: clinical surveillance and environmental sampling. Clin Infect Dis 1999, 29:1323-1326.
17. Phetsouvanh R, Phongmany S, Soukaloun D, et al. Causes of community-acquired bacteremia and patterns of antimicrobial resistance in Vientiane, Laos. Am J Trop Med Hyg 2006, 75:978-985.
18. Wuthiekanun V, Pheaktra N, Putchhat H, et al. Burkholderia pseudomallei antibodies in children, Cambodia. Emerg Infect Dis 2008, 14:301-303.
19. Stoesser N, Pocock J, Moore CE, et al. Pediatric suppurative parotitis in Cambodia between 2007 and 2011. Pediatr Infect Dis J 2012, 31:865-868.
20. Cheng AC, Currie BJ Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005, 18:383-416.
21. Cherian T, Raghupathy P, John TJ Plague in India. Lancet 1995, 345:258-259.
22. Dance DA, Sanders D, Pitt TL, et al. Burkholderia pseudomallei and Indian plague-like illness. Lancet 1995, 346:904-905.
23. Athan E, Allworth AM, Engler C, et al. Melioidosis in tsunami survivors. Emerg Infect Dis 2005, 11:1638-1639.
24. Le Hello S, Currie BJ, Godoy D, et al. Melioidosis in New Caledonia. Emerg Infect Dis 2005, 11:1607-1609.
25. Inglis TJ, Rolim DB, Sousa Ade Q Melioidosis in the Americas. Am J Trop Med Hyg 2006, 75:947-954.
26. Borgherini GP, Poubeau F, Paganin S, et al. Melioidosis: an imported case from Madagascar. J Travel Med 2006, 13:318-320.
27. Salam AP, Khan N, Malnick H, et al. Melioidosis acquired by traveler to Nigeria. Emerg Infect Dis 2011, 17:1296-1298.
28. Boonsawat W, Boonma P, Tangdajahiran T, et al. Community-acquired pneumonia in adults at Srinagarind Hospital. J Med Assoc Thai 1990, 73:345-352.
29. Currie BJ, Fisher DA, Howard DM, et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop 2000, 74:121-127.
30. Dance DA Melioidosis: the tip of the iceberg?. Clin Microbiol Rev 1991, 4:52-60.
31. Currie B, Smith Vaughan H, Golledge C, et al. Pseudomonas pseudomallei isolates collected over 25 years from a non-tropical endemic focus show clonality on the basis of ribotyping. Epidemiol Infect 1994, 113:307-312.
32. Clayton AJ, Lisella RS, Martin DG Melioidosis: a serological survey in military personnel. Mil Med 1973, 138:24-26.
33. Wuthiekanun V, Smith MD, Dance DA, et al. Isolation of Pseudomonas pseudomallei from soil in north-eastern Thailand. Trans R Soc Trop Med Hyg 1995, 89:41-43.
34. Kaestli M, Mayo M, Harrington G, et al. Landscape changes influence the occurrence of the melioidosis bacterium Burkholderia pseudomallei in soil in northern Australia. PLoS Negl Trop Dis 2009, 3:e364.
35. Thomas AD, Forbes Faulkner J, Parker M Isolation of Pseudomonas pseudomallei from clay layers at defined depths. Am J Epidemiol 1979, 110:515-521.
36. Inglis TJ, Mee B, Chang B The environmental microbiology of melioidosis. Rev Med Microbiol 2001, 12:13-20.
37. Kaestli M, Schmid M, Mayo M, et al. Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. Environ Microbiol 2012, 14:2058-2070.
38. Gamage AM, Shui G, Wenk MR, Chua KL N-Octanoylhomoserine lactone signalling mediated by the BpsI-BpsR quorum sensing system plays a major role in biofilm formation of Burkholderia pseudomallei. Microbiology 2011, 157(pt 4):1176-1186.
39. Suputtamongkol Y, Hall AJ, Dance DA, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol 1994, 23:1082-1090.
40. Limmathurotsakul D, Kanoksil M, Wuthiekanun V, et al. Activities of daily living associated with acquisition of melioidosis in northeast Thailand: a matched case-control study. PLoS Negl Trop Dis 2013, 7:e2072.
41. Howe C, Sampath A, Spotnitz M The pseudomallei group: a review. J Infect Dis 1971, 124:598-606.
42. Currie BJ, Jacups SP Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis 2003, 9:1538-1542.
43. Cheng AC, Currie BJ, Dance DA, et al. Clinical definitions of melioidosis. Am J Trop Med Hyg 2013, 88:411-413.
44. Inglis TJ, Garrow SC, Henderson M, et al. Burkholderia pseudomallei traced to water treatment plant in Australia. Emerg Infect Dis 2000, 6:56-59.
45. Currie BJ, Mayo M, Anstey NM, et al. A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. Am J Trop Med Hyg 2001, 65:177-179.
46. Currie BJ, Fisher DA, Anstey NM, et al. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 2000, 94:301-304.
47. Sookpranee M, Lumbiganon P, Boonma P Nosocomial contamination of Pseudomonas pseudomallei in the patients at Srinagarind Hospital. Melioidosis 1989, 204-210. Bangkok Medical, Bangkok. S. Punyagupta, T. Sirisanthana, B. Stapatayavong (Eds.).
48. Ashdown LR, Guard RW The prevalence of human melioidosis in Northern Queensland. Am J Trop Med Hyg 1984, 33:474-478.
49. Wuthiekanun V, Chierakul W, Langa S, et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am J Trop Med Hyg 2006, 74:1074-1075.
50. Ulett GC, Currie BJ, Clair TW, et al. Burkholderia pseudomallei virulence: definition, stability and association with clonality. Microbes Infect 2001, 3:621-631.
51. Holden MT, Titball RW, Peacock SJ, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 2004, 101:14240-14245.
52. Tuanyok A, Auerbach RK, Brettin TS, et al. A horizontal gene transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol 2007, 189:9044-9049.
53. Nandi T, Ong C, Singh AP, et al. A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence. PLoS Pathog 2010, 6.
54. Wiersinga WJ, van der Poll T, White NJ, et al. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006, 4:272-282.
55. DeShazer D, Brett PJ, Woods DE The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 1998, 30:1081-1100.
56. Reckseidler SL, DeShazer D, Sokol PA, et al. Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun 2001, 69:34-44.
57. DeShazer D, Waag DM, Fritz DL, et al. Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant. Microb Pathog 2001, 30:253-269.
58. Stevens MP, Wood MW, Taylor LA, et al. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol 2002, 46:649-659.
59. Burtnick MN, Brett PJ, Harding SV, et al. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun 2011, 79:1512-1525.
60. Ulrich RL, DeShazer D, Brueggemann EE, et al. Role of quorum sensing in the pathogenicity of Burkholderia pseudomallei. J Med Microbiol 2004, 53:1053-1064.
61. Cruz-Migoni A, Hautbergue GM, Artymiuk PJ, et al. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science 2011, 334:821-824.
62. Stevens MP, Stevens JM, Jeng RL, et al. Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei. Mol Microbiol 2005, 56:40-53.
63. Chantratita N, Wuthiekanun V, Boonbumrung K, et al. Biological relevance of colony morphology and phenotypic switching by Burkholderia pseudomallei. J Bacteriol 2007, 189:807-817.
64. Nuntayanuwat S, Dharakul T, Chaowagul W, et al. Polymorphism in the promoter region of tumor necrosis factor-alpha gene is associated with severe melioidosis. Hum Immunol 1999, 60:979-983.
65. Santanirand P, Harley VS, Dance DA, et al. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect Immun 1999, 67:3593-3600.
66. Wiersinga WJ, Wieland CW, Dessing MC, et al. Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Med 2007, 4:e248.
67. West TE, Chierakul W, Chantratita N, et al. Toll-like receptor 4 region genetic variants are associated with susceptibility to melioidosis. Genes Immun 2012, 13:38-46.
68. Wiersinga WJ, Dessing MC, Kager PA, et al. High-throughput mRNA profiling characterizes the expression of inflammatory molecules in sepsis caused by Burkholderia pseudomallei. Infect Immun 2007, 75:3074-3079.
69. Barnes JL, Warner J, Melrose W, et al. Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin Immunol 2004, 113:22-28.
70. Limmathurotsakul D, Chaowagul W, Chierakul W, et al. Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis 2006, 43:979-986.
71. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999, 29:408-413.
72. Lumbiganon P, Viengnondha S Clinical manifestations of melioidosis in children. Pediatr Infect Dis J 1995, 14:136-140.
73. Edmond K, Bauert P, Currie B Paediatric melioidosis in the Northern Territory of Australia: an expanding clinical spectrum. J Paediatr Child Health 2001, 37:337-341.
74. Easton A, Haque A, Chu K, et al. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 2007, 195:99-107.
75. Tarlow MJ, Lloyd J Melioidosis and chronic granulomatous disease. Proc R Soc Med 1971, 64:19-20.
76. Meumann EM, Cheng AC, Ward L, Currie BJ Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis 2012, 54:362-369.
77. Price EP, Sarovich DS, Mayo M, et al. In vivo evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. MBio 2013, 4. e00388-e00313.
78. Holland DJ, Wesley A, Drinkovic D, et al. Cystic fibrosis and Burkholderia pseudomallei: an emerging problem?. Clin Infect Dis 2002, 35:e138-e140.
79. Gibney KB, Cheng AC, Currie BJ Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. Clin Infect Dis 2008, 47:603-609.
80. Dance DA, Davis TM, Wattanagoon Y, et al. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J Infect Dis 1989, 159:654-660.
81. Morse LP, Moller CC, Harvey E, et al. Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. J Urol 2009, 182:542-547.
82. Currie BJ, Fisher DA, Howard DM, et al. Neurological melioidosis. Acta Trop 2000, 74:145-151.
83. Koszyca B, Currie BJ, Blumbergs PC The neuropathology of melioidosis: two cases and a review of the literature. Clin Neuropathol 2004, 23:195-203.
84. Chadwick DR, Ang B, Sitoh YY, et al. Cerebral melioidosis in Singapore: a review of five cases. Trans R Soc Trop Med Hyg 2002, 96:72-76.
85. Ngauy V, Lemeshev Y, Sadkowski L, et al. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 2005, 43:970-972.
86. Lowe P, Engler C, Norton R Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei. J Clin Microbiol 2002, 40:4625-4627.
87. Cunningham SA, Patel R Importance of using Bruker's security-relevant library for Biotyper identification of Burkholderia pseudomallei, Brucella species, and Francisella tularensis. J Clin Microbiol 2013, 51:1639-1640.
88. Ashdown LR An improved screening technique for isolation of Pseudomonas pseudomallei from clinical specimens. Pathology 1979, 11:293-297.
89. Peacock SJ, Chieng G, Cheng AC, et al. Comparison of Ashdown's medium, Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol 2005, 43:5359-5361.
90. Dance DA, Wuthiekanun V, Naigowit P, et al. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol 1989, 42:645-648.
91. Smith MD, Wuthiekanun V, Walsh AL, et al. Latex agglutination for rapid detection of Pseudomonas pseudomallei antigen in urine of patients with melioidosis. J Clin Pathol 1995, 48:174-176.
92. Wuthiekanun V, Desakorn V, Wongsuvan G, et al. Rapid immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab Immunol 2005, 12:555-556.
93. Sirisinha S, Anuntagool N, Dharakul T, et al. Recent developments in laboratory diagnosis of melioidosis. Acta Trop 2000, 74:235-245.
94. Kaestli M, Richardson LJ, Colman RE, et al. Comparison of TaqMan PCR assays for detection of the melioidosis agent Burkholderia pseudomallei in clinical specimens. J Clin Microbiol 2012, 50:2059-2062.
95. Cheng AC, O'Brien M, Freeman K, et al. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg 2006, 74:330-334.
96. Chantratita N, Wuthiekanun V, Thanwisai A, et al. Accuracy of enzyme-linked immunosorbent assay using crude and purified antigens for serodiagnosis of melioidosis. Clin Vaccine Immunol 2007, 14:110-113.
97. White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989, 2:697-701.
98. Lipsitz R, Garges S, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis 2012, 18:e2.
99. Sookpranee M, Boonma P, Susaengrat W, et al. Multicenter prospective randomized trial comparing ceftazidime plus cotrimoxazole with chloramphenicol plus doxycycline and cotrimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992, 36:158-162.
100. Chierakul W, Anunnatsiri S, Short JM, et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 2005, 41:1105-1113.
101. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994, 19:846-853.
102. Smith MD, Wuthiekanun V, Walsh AL, et al. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother 1994, 33:145-149.
103. Smith MD, Wuthiekanun V, Walsh AL, et al. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother 1996, 37:611-615.
104. Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999, 29:381-387.
105. Cheng AC, Fisher DA, Anstey NM, et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 2004, 48:1763-1765.
106. Huffam S, Jacups SP, Kittler P, et al. Out of hospital treatment of patients with melioidosis using ceftazidime in 24 helastomeric infusors, via peripherally inserted central catheters. Trop Med Int Health 2004, 9:715-717.
107. Sarovich DS, Ward L, Price EP, et al. Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare. J Clin Microbiol 2014, 52:650-653.
108. Chaowagul W, Suputtamongkol Y, Dance DA, et al. Relapse in melioidosis: incidence and risk factors. J Infect Dis 1993, 168:1181-1185.
109. Cheng AC, Chierakul W, Chaowagul W, et al. Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis. Am J Trop Med Hyg 2008, 78:208-209.
110. Chaowagul W, Simpson AJ, Suputtamongkol Y, et al. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin Infect Dis 1999, 29:375-380.
111. Chaowagul W, Chierakul W, Simpson AJ, et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 2005, 49:4020-4025.
112. Chusri S, Hortiwakul T, Charoenmak B, Silpapojakul K Outcomes of patients with melioidosis treated with cotrimoxazole alone for eradication therapy. Am J Trop Med Hyg 2012, 87:927-932.
113. Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014, 383:807-814.
114. Cheng AC, Stephens DP, Anstey NM, et al. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004, 38:32-37.
115. Cheng AC, Limmathurotsakul D, Chierakul W, et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 2007, 45:308-314.
116. Peacock SJ, Schweizer HP, Dance DA, et al. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis 2008, 14:e2.
117. Peacock S, Limmathurotsakul D, Lubell Y, et al. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis 2012, 6:e1488.
118. Choh LC, Ong GH, Vellasamy KM, et al. Burkholderia vaccines: are we moving forward?. Front Cell Infect Microbiol 2013, 3:5.
119. Wheelis M First shots fired in biological warfare. Nature 1998, 395:213.
120. Godoy D, Randle G, Simpson AJ, et al. Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol 2003, 41:2068-2079.
121. Nierman WC, DeShazer D, Kim HS, et al. Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A 2004, 101:14246-14251.
122. Howe C, Miller WR Human glanders: report of six cases. Ann Intern Med 1947, 26:93-115.
123. Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med 2001, 345:256-258.
124. Fritz DL, Vogel P, Brown DR, et al. Mouse model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei). Vet Pathol 2000, 37:626-636.
125. Burtnick MN, Brett PJ, Woods DE Molecular and physical characterization of Burkholderia mallei O antigens. J Bacteriol 2002, 184:849-852.
126. Lopez J, Copps J, Wilhelmsen C, et al. Characterization of experimental equine glanders. Microbes Infect 2003, 5:1125-1131.
127. Robins GD A study of chronic glanders in man with report of a case: analysis of 156 cases collected from the literature. Stud R Victoria Hosp Montreal 1906, 2:1-98.
128. Pal V, Kumar S, Malik P, Rai GP Evaluation of recombinant proteins of Burkholderia mallei for serodiagnosis of glanders. Clin Vaccine Immunol 2012, 19:1193-1198.
129. Heine HS, England MJ, Waag DM, et al. In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Antimicrob Agents Chemother 2001, 45:2119-2121.
130. Burtnick MN, Heiss C, Roberts RA, et al. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol 2012, 2:108.
131. Wiersinga WJ, Currie BJ, Peacock SJ Melioidosis. N Engl J Med 2012, 367:1030-1039.
132. Whitmore A, Krishnaswami CS An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. Indian Med Gaz 1912, 47:262-267.
133. Currie BJ, Ward L, Cheng AC The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20-year Darwin prospective study. PLoS Negl Trop Dis 2010, 4:e900.
134. Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989, 159:890-899.
135. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, et al. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg 2010, 82:1113-1117.
136. Stoesser N, Pocock J, Moore CE, et al. Pediatric suppurative parotitis in Cambodia between 2007 and 2011. Pediatr Infect Dis J 2012, 31:865-868.
137. Cheng AC, Currie BJ Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005, 18:383-416.
138. Inglis TJ, Rolim DB, Sousa Ade Q Melioidosis in the Americas. Am J Trop Med Hyg 2006, 75:947-954.
139. Dance DA Melioidosis: the tip of the iceberg?. Clin Microbiol Rev 1991, 4:52-60.
140. Kaestli M, Schmid M, Mayo M, et al. Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. Environ Microbiol 2012, 14:2058-2070.
141. Suputtamongkol Y, Hall AJ, Dance DA, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol 1994, 23:1082-1090.
142. Limmathurotsakul D, Kanoksil M, Wuthiekanun V, et al. Activities of daily living associated with acquisition of melioidosis in northeast Thailand: a matched case-control study. PLoS Negl Trop Dis 2013, 7:e2072.
143. Cheng AC, Currie BJ, Dance DA, et al. Clinical definitions of melioidosis. Am J Trop Med Hyg 2013, 88:411-413.
144. Currie BJ, Fisher DA, Anstey NM, et al. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 2000, 94:301-304.
145. Wuthiekanun V, Chierakul W, Langa S, et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am J Trop Med Hyg 2006, 74:1074-1075.
146. Holden MT, Titball RW, Peacock SJ, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 2004, 101:14240-14245.
147. Tuanyok A, Auerbach RK, Brettin TS, et al. A horizontal gene transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol 2007, 189:9044-9049.
148. Nandi T, Ong C, Singh AP, et al. A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence. PLoS Pathog 2010, 6:e1000845.
149. Wiersinga WJ, van der Poll T, White NJ, et al. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006, 4:272-282.
150. Stevens MP, Wood MW, Taylor LA, et al. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol 2002, 46:649-659.
151. Burtnick MN, Brett PJ, Harding SV, et al. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun 2011, 79:1512-1525.
152. Limmathurotsakul D, Chaowagul W, Chierakul W, et al. Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis 2006, 43:979-986.
153. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999, 29:408-413.
154. Easton A, Haque A, Chu K, et al. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 2007, 195:99-107.
155. Meumann EM, Cheng AC, Ward L, Currie BJ Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis 2012, 54:362-369.
156. Price EP, Sarovich DS, Mayo M, et al. In vivo evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. MBio 2013, 4. e00388-e00313.
157. Holland DJ, Wesley A, Drinkovic D, et al. Cystic fibrosis and Burkholderia pseudomallei: an emerging problem?. Clin Infect Dis 2002, 35:e138-e140.
158. Gibney KB, Cheng AC, Currie BJ Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. Clin Infect Dis 2008, 47:603-609.
159. Dance DA, Davis TM, Wattanagoon Y, et al. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J Infect Dis 1989, 159:654-660.
160. Morse LP, Moller CC, Harvey E, et al. Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. J Urol 2009, 182:542-547.
161. Currie BJ, Fisher DA, Howard DM, et al. Neurological melioidosis. Acta Trop 2000, 74:145-151.
162. Ngauy V, Lemeshev Y, Sadkowski L, et al. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 2005, 43:970-972.
163. Lowe P, Engler C, Norton R Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei. J Clin Microbiol 2002, 40:4625-4627.
164. Cunningham SA, Patel R Importance of using Bruker's security-relevant library for Biotyper identification of Burkholderia pseudomallei, Brucella species, and Francisella tularensis. J Clin Microbiol 2013, 51:1639-1640.
165. Peacock SJ, Chieng G, Cheng AC, et al. Comparison of Ashdown's medium, Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol 2005, 43:5359-5361.
166. Smith MD, Wuthiekanun V, Walsh AL, et al. Latex agglutination for rapid detection of Pseudomonas pseudomallei antigen in urine of patients with melioidosis. J Clin Pathol 1995, 48:174-176.
167. Wuthiekanun V, Desakorn V, Wongsuvan G, et al. Rapid immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab Immunol 2005, 12:555-556.
168. Cheng AC, O'Brien M, Freeman K, et al. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg 2006, 74:330-334.
169. White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989, 2:697-701.
170. Lipsitz R, Garges S, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis 2012, 18:e2.
171. Chierakul W, Anunnatsiri S, Short JM, et al. Two ran-domized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 2005, 41:1105-1113.
172. Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999, 29:381-387.
173. Cheng AC, Fisher DA, Anstey NM, et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 2004, 48:1763-1765.
174. Sarovich DS, Ward L, Price EP, et al. Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare. J Clin Microbiol 2014, 52:650-653.
175. Cheng AC, Chierakul W, Chaowagul W, et al. Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis. Am J Trop Med Hyg 2008, 78:208-209.
176. Chaowagul W, Simpson AJ, Suputtamongkol Y, et al. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin Infect Dis 1999, 29:375-380.
177. Chaowagul W, Chierakul W, Simpson AJ, et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 2005, 49:4020-4025.
178. Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014, 383:807-814.
179. Peacock SJ, Schweizer HP, Dance DA, et al. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis 2008, 14:e2.
180. Peacock S, Limmathurotsakul D, Lubell Y, et al. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis 2012, 6:e1488.
181. Godoy D, Randle G, Simpson AJ, et al. Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol 2003, 41:2068-2079.
182. Nierman WC, DeShazer D, Kim HS, et al. Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A 2004, 101:14246-14251.
183. Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med 2001, 345:256-258.
184. Lopez J, Copps J, Wilhelmsen C, et al. Characterization of experimental equine glanders. Microbes Infect 2003, 5:1125-1131.